GeneToBe

Executive Summary

GeneToBe, Inc. is a private biotechnology company spun out of the University of Michigan, headquartered in Ann Arbor, with operations in San Diego. The company is dedicated to developing novel, lifelong therapies for patients with significant unmet medical needs, focusing on cystic fibrosis (CF), Usher syndrome, and metabolic dysfunction-associated steatohepatitis (MASH). Leveraging its expertise in genetics and genomics, GeneToBe aims to deliver transformative treatments that address the root causes of these debilitating conditions. Despite limited public information on funding or pipeline specifics, the company’s focus on rare and orphan diseases positions it in a high-value therapeutic space with substantial market potential. GeneToBe’s progress remains early-stage, and its success will depend on advancing preclinical programs into clinical development and securing partnerships or financing to support growth.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Cystic Fibrosis Program40% success
• Q2 2026Preclinical Data Presentation for Usher Syndrome Gene Therapy50% success
• Q1 2026Series A or Partnering Deal to Advance MASH Program35% success